Increased odds of adverse outcomes seen for Hispanic/Latinos, African-American Blacks versus white patients.
The FDA issued a clinical hold for a trial evaluating a universal CAR T-cell product in patients with relapsed or refractory multiple myeloma after 1 patient died.
MM cells expressing high levels of migration inhibitory factor may have poorer responses to proteasome inhibitors, resulting in adverse patient outcomes.
For patients with initial myeloma cast nephropathy, renal response rates did not significantly vary after doublet vs triplet bortezomib-based treatments.
Despite thromboprophylaxis, patients who have newly developed multiple myeloma are at an “unacceptably high VTE risk”, study results suggest.